These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 23765220)

  • 21. Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties.
    Guardiola-Lemaitre B; De Bodinat C; Delagrange P; Millan MJ; Munoz C; Mocaër E
    Br J Pharmacol; 2014 Aug; 171(15):3604-19. PubMed ID: 24724693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathophysiology of depression: role of sleep and the melatonergic system.
    Srinivasan V; Pandi-Perumal SR; Trakht I; Spence DW; Hardeland R; Poeggeler B; Cardinali DP
    Psychiatry Res; 2009 Feb; 165(3):201-14. PubMed ID: 19181389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine.
    De Berardis D; Di Iorio G; Acciavatti T; Conti C; Serroni N; Olivieri L; Cavuto M; Martinotti G; Janiri L; Moschetta FS; Conti P; Di Giannantonio M
    CNS Neurol Disord Drug Targets; 2011 Feb; 10(1):119-32. PubMed ID: 20874703
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development.
    de Bodinat C; Guardiola-Lemaitre B; Mocaër E; Renard P; Muñoz C; Millan MJ
    Nat Rev Drug Discov; 2010 Aug; 9(8):628-42. PubMed ID: 20577266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic mechanisms involved in the antidepressant effects of agomelatine.
    Tardito D; Molteni R; Popoli M; Racagni G
    Eur Neuropsychopharmacol; 2012; 22 Suppl 3():S482-6. PubMed ID: 22867907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic agomelatine treatment corrects the abnormalities in the circadian rhythm of motor activity and sleep/wake cycle induced by prenatal restraint stress in adult rats.
    Mairesse J; Silletti V; Laloux C; Zuena AR; Giovine A; Consolazione M; van Camp G; Malagodi M; Gaetani S; Cianci S; Catalani A; Mennuni G; Mazzetta A; van Reeth O; Gabriel C; Mocaër E; Nicoletti F; Morley-Fletcher S; Maccari S
    Int J Neuropsychopharmacol; 2013 Mar; 16(2):323-38. PubMed ID: 22310059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activation of Melatonin Receptors Reduces Relapse-Like Alcohol Consumption.
    Vengeliene V; Noori HR; Spanagel R
    Neuropsychopharmacology; 2015 Dec; 40(13):2897-906. PubMed ID: 25994077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The preclinical discovery and development of agomelatine for the treatment of depression.
    Konstantakopoulos G; Dimitrakopoulos S; Michalopoulou PG
    Expert Opin Drug Discov; 2020 Oct; 15(10):1121-1132. PubMed ID: 32568567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Agomelatine, a melatonin agonist with antidepressant properties.
    Dubovsky SL; Warren C
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1533-40. PubMed ID: 19758108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Agomelatine: a potential novel approach for the treatment of memory disorder in neurodegenerative disease.
    Su Q; Li T; Liu GW; Zhang YL; Guo JH; Wang ZJ; Wu MN; Qi JS
    Neural Regen Res; 2023 Apr; 18(4):727-733. PubMed ID: 36204828
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Melatonergic Receptors (Mt1/Mt2) as a Potential Additional Target of Novel Drugs for Depression.
    Boiko DI; Shkodina AD; Hasan MM; Bardhan M; Kazmi SK; Chopra H; Bhutra P; Baig AA; Skrypnikov AM
    Neurochem Res; 2022 Oct; 47(10):2909-2924. PubMed ID: 35689787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative Review of Approved Melatonin Agonists for the Treatment of Circadian Rhythm Sleep-Wake Disorders.
    Williams WP; McLin DE; Dressman MA; Neubauer DN
    Pharmacotherapy; 2016 Sep; 36(9):1028-41. PubMed ID: 27500861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Agomelatine, an innovative pharmacological response to unmet needs.
    Le Strat Y; Gorwood P
    J Psychopharmacol; 2008 Sep; 22(7 Suppl):4-8. PubMed ID: 18753276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beneficial behavioural and neurogenic effects of agomelatine in a model of depression/anxiety.
    Rainer Q; Xia L; Guilloux JP; Gabriel C; Mocaër E; Hen R; Enhamre E; Gardier AM; David DJ
    Int J Neuropsychopharmacol; 2012 Apr; 15(3):321-35. PubMed ID: 21473810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture.
    Descamps A; Rousset C; Millan MJ; Spedding M; Delagrange P; Cespuglio R
    Psychopharmacology (Berl); 2009 Jul; 205(1):93-106. PubMed ID: 19370342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Agomelatine in the treatment of seasonal affective disorder.
    Pjrek E; Winkler D; Konstantinidis A; Willeit M; Praschak-Rieder N; Kasper S
    Psychopharmacology (Berl); 2007 Mar; 190(4):575-9. PubMed ID: 17171557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Like melatonin, agomelatine (S20098) increases the amplitude of oscillations of two clock outputs: melatonin and temperature rhythms.
    Castanho A; Bothorel B; Seguin L; Mocaër E; Pévet P
    Chronobiol Int; 2014 Apr; 31(3):371-81. PubMed ID: 24328729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.
    Kasper S; Hajak G; Wulff K; Hoogendijk WJ; Montejo AL; Smeraldi E; Rybakowski JK; Quera-Salva MA; Wirz-Justice AM; Picarel-Blanchot F; Baylé FJ
    J Clin Psychiatry; 2010 Feb; 71(2):109-20. PubMed ID: 20193645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Agomelatine].
    Tessmer M
    Med Monatsschr Pharm; 2009 Aug; 32(8):282-8. PubMed ID: 19777735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Agomelatine, melatonin and depressive disorder.
    Norman TR
    Expert Opin Investig Drugs; 2013 Apr; 22(4):407-10. PubMed ID: 23484857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.